JP2019515908A - カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 - Google Patents

カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 Download PDF

Info

Publication number
JP2019515908A
JP2019515908A JP2018554585A JP2018554585A JP2019515908A JP 2019515908 A JP2019515908 A JP 2019515908A JP 2018554585 A JP2018554585 A JP 2018554585A JP 2018554585 A JP2018554585 A JP 2018554585A JP 2019515908 A JP2019515908 A JP 2019515908A
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515908A5 (enExample
Inventor
キム，フィリップ・アール
ボイト，エリック
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2019515908A publication Critical patent/JP2019515908A/ja
Publication of JP2019515908A5 publication Critical patent/JP2019515908A5/ja
Priority to JP2021140920A priority Critical patent/JP2022000428A/ja
Priority to JP2023179367A priority patent/JP2024020212A/ja
Priority to JP2025134679A priority patent/JP2025163273A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2018554585A 2016-04-20 2017-04-20 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 Pending JP2019515908A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021140920A JP2022000428A (ja) 2016-04-20 2021-08-31 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
JP2023179367A JP2024020212A (ja) 2016-04-20 2023-10-18 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法
JP2025134679A JP2025163273A (ja) 2016-04-20 2025-08-13 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325200P 2016-04-20 2016-04-20
US62/325,200 2016-04-20
PCT/US2017/028646 WO2017184871A1 (en) 2016-04-20 2017-04-20 Carbidopa and l-dopa prodrugs and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021140920A Division JP2022000428A (ja) 2016-04-20 2021-08-31 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法

Publications (2)

Publication Number Publication Date
JP2019515908A true JP2019515908A (ja) 2019-06-13
JP2019515908A5 JP2019515908A5 (enExample) 2020-06-18

Family

ID=58668985

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018554585A Pending JP2019515908A (ja) 2016-04-20 2017-04-20 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
JP2021140920A Pending JP2022000428A (ja) 2016-04-20 2021-08-31 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
JP2023179367A Pending JP2024020212A (ja) 2016-04-20 2023-10-18 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法
JP2025134679A Pending JP2025163273A (ja) 2016-04-20 2025-08-13 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021140920A Pending JP2022000428A (ja) 2016-04-20 2021-08-31 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
JP2023179367A Pending JP2024020212A (ja) 2016-04-20 2023-10-18 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法
JP2025134679A Pending JP2025163273A (ja) 2016-04-20 2025-08-13 カルビドパ及びｌ－ドパプロドラッグ並びに使用方法

Country Status (4)

Country Link
US (1) US20190224220A1 (enExample)
EP (2) EP4295909A3 (enExample)
JP (4) JP2019515908A (enExample)
WO (1) WO2017184871A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3209302T3 (da) 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CA3117983A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020115753A1 (en) * 2018-12-05 2020-06-11 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP2024010252A (ja) 2021-03-10 2024-01-24 田辺三菱製薬株式会社 パーキンソン病治療のための組合せ医薬
TW202428256A (zh) * 2022-11-14 2024-07-16 大陸商江蘇恒瑞醫藥股份有限公司 左旋多巴的前藥

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000863A1 (ja) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. プロドラッグ、その医薬としての使用、およびその製法
JP2007504143A (ja) * 2003-08-29 2007-03-01 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
JP2007509972A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン レボドパ及びカルビドパの投与
JP2008505898A (ja) * 2004-07-06 2008-02-28 アボット・ラボラトリーズ Ｈｉｖプロテアーゼ阻害薬のプロドラッグ
JP2013545745A (ja) * 2010-11-15 2013-12-26 ニューロダーム リミテッド Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) * 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) * 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU2003293423A1 (en) * 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
KR101698028B1 (ko) * 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
DK3209302T3 (da) * 2014-10-21 2019-05-13 Abbvie Inc Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000863A1 (ja) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. プロドラッグ、その医薬としての使用、およびその製法
JP2007504143A (ja) * 2003-08-29 2007-03-01 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
JP2007509972A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン レボドパ及びカルビドパの投与
JP2008505898A (ja) * 2004-07-06 2008-02-28 アボット・ラボラトリーズ Ｈｉｖプロテアーゼ阻害薬のプロドラッグ
JP2013545745A (ja) * 2010-11-15 2013-12-26 ニューロダーム リミテッド Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHARMACEUTICAL RESEARCH, vol. 10(9), JPN6021007107, 1993, pages 1350 - 1355, ISSN: 0004623349 *
日本産婦人科学会雑誌, vol. 52(12), JPN6021007106, 2000, pages 433 - 437, ISSN: 0004623348 *

Also Published As

Publication number Publication date
WO2017184871A1 (en) 2017-10-26
JP2022000428A (ja) 2022-01-04
US20190224220A1 (en) 2019-07-25
EP4295909A2 (en) 2023-12-27
EP3445346A1 (en) 2019-02-27
EP4295909A3 (en) 2024-07-17
JP2025163273A (ja) 2025-10-28
JP2024020212A (ja) 2024-02-14
WO2017184871A9 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
JP2019515908A (ja) カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
JP6932227B2 (ja) カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
AU2022200291A1 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
KR101411422B1 (ko) 중수소화 카테콜아민 유도체 및 이를 포함하는 의약품
US9765020B2 (en) Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
SK281697B6 (sk) Soľ organickej bázy a n,n'-diacetylcystínu, spôsob jej výroby, jej použitie a farmaceutický prostriedok s jej obsahom
JP2012087124A (ja) 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
US20230157989A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US20190381028A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
CN107400126A (zh) 新型噁唑烷酮类化合物及其制备方法和在医学上的应用
CN102153538B (zh) 苯并环衍生物
WO2014116594A1 (en) Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
FI90531C (fi) Menetelmä terapeuttisesti käyttökelpoisten -(fluorimetyleeni)-5-hydroksitryptofaanijohdannaisten valmistamiseksi
CN105530929B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在预防和治疗糖尿病中的用途
TWI730019B (zh) 噻二唑衍生物類ｄｐｐ-ｉｖ抑制劑的結晶及其用途
CN101450914B (zh) 苯甲酸衍生物
CN102702126B (zh) 一种可用于麻醉剂的化合物
JPWO2019182506A5 (enExample)
TW200413291A (en) Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211026